Mirum Pharmaceuticals Toekomstige groei
Future criteriumcontroles 5/6
Mirum Pharmaceuticals is forecast to grow earnings and revenue by 69.3% and 24.9% per annum respectively. EPS is expected to grow by 66.8% per annum. Return on equity is forecast to be -10.2% in 3 years.
Belangrijke informatie
69.3%
Groei van de winst
66.8%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | 24.9% |
| Toekomstig rendement op eigen vermogen | -10.2% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 17 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?
Nov 03
Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Oct 04Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Jul 17Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth
Jul 13Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry
May 28Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 509 | 52 | 23 | 46 | 7 |
| 12/31/2025 | 405 | -38 | -23 | -18 | 10 |
| 12/31/2024 | 316 | -85 | -85 | -13 | 10 |
| 6/30/2024 | 264 | -109 | -39 | -23 | N/A |
| 3/31/2024 | 224 | -159 | -42 | -37 | N/A |
| 12/31/2023 | 186 | -163 | -91 | -71 | N/A |
| 9/30/2023 | 145 | -164 | -104 | -89 | N/A |
| 6/30/2023 | 116 | -176 | -112 | -96 | N/A |
| 3/31/2023 | 96 | -129 | -115 | -99 | N/A |
| 12/31/2022 | 77 | -136 | -120 | -120 | N/A |
| 9/30/2022 | 52 | -42 | -138 | -119 | N/A |
| 6/30/2022 | 39 | -53 | -146 | -127 | N/A |
| 3/31/2022 | 32 | -70 | -166 | -147 | N/A |
| 12/31/2021 | 19 | -84 | -152 | -133 | N/A |
| 9/30/2021 | 16 | -179 | -136 | -136 | N/A |
| 6/30/2021 | 11 | -153 | -119 | -119 | N/A |
| 3/31/2021 | N/A | -132 | -96 | -96 | N/A |
| 12/31/2020 | N/A | -103 | -89 | -89 | N/A |
| 9/30/2020 | N/A | -84 | -67 | -66 | N/A |
| 6/30/2020 | N/A | -78 | -65 | -64 | N/A |
| 3/31/2020 | N/A | -68 | -56 | -55 | N/A |
| 12/31/2019 | N/A | -53 | -40 | -39 | N/A |
| 9/30/2019 | N/A | -61 | -38 | -26 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: MIRM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Winst versus markt: MIRM is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: MIRM is expected to become profitable in the next 3 years.
Omzet versus markt: MIRM's revenue (24.9% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: MIRM's revenue (24.9% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: MIRM is forecast to be unprofitable in 3 years.